Roche shells out $200M for rights to Vaccibody's neoantigen cancer vaccine

Nicole DeFeudis

Editor

Roche’s Genentech arm is putting down $200 million in upfronts and near-term payments — and potentially $515M more down the road — for global rights to Norwegian …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche shells out $200M for rights to Vaccibody's neoantigen cancer vaccine

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Roche shells out $200M for rights to Vac­ci­body's neoanti­gen can­cer vac­cine

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Roche shells out $200M for rights to Vaccibody's neoantigen cancer vaccine